A Study of SHR3680 in Treating Patients With Hormone Sensitive Prostate Cancer

NCT03520478 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

654

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer
Hormone-Dependent Prostate Cancer

Interventions

DRUG: SHR3680
DRUG: Bicalutamide

Sponsor

Jiangsu HengRui Medicine Co., Ltd.